[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.149.128. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
April 23 2008

Antipsychotic-Induced Weight Gain in Patients With Schizophrenia

JAMA. 2008;299(16):1898-1900. doi:10.1001/jama.299.16.1899-a

To the Editor: In their clinical trial, Dr Wu and colleagues1 reported clinically significant benefits of metformin and lifestyle interventions in reducing antipsychotic-induced weight gain in patients with schizophrenia. In addition to the mechanisms for this finding that were considered by the authors, the effect of these interventions on levels of insulinlike growth factor 1 (IGF-1) deserves further exploration. Although an animal study suggests that exercise may increase circulating IGF-1 levels,2 a small study in healthy men suggests that metformin decreases IGF-1.3 Although exercise and metformin resulted in similar short-term benefits on antipsychotic-induced weight gain in the study by Wu et al, their long-term effects on IGF-1 might be important to consider in these patients.

×